Re: Portola Pharmaceuticals Presents New In Vitro Data
UptoDate - which was s reference used by many physicians - still is recommending Andexxa OR PCC’s! This study should make these KOL’s change their recommendations. So a very important news release by PTLA.
Here is the actual current text from UpToDate:
●Life-threatening bleeding – For patients who are at imminent risk of death from bleeding associated with direct factor Xa inhibitor anticoagulation, we suggest andexanet alfa or an unactivated 4-factor PCC (table 3).
•Dosing for andexanet, at one of two dose levels based on dose and timing of the factor Xa inhibitor, is described below. (See 'Andexanet alfa' below.)
•Dosing for unactivated 4 factor PCC is 25 to 50 units/kg or fixed dose of 2,000 units, as discussed below. (See 'PCCs and aPCCs' below.)
There is insufficient evidence about risks and benefits to strongly favor either 4-factor PCC or andexanet over the other.
Well there is evidence now!